Table 2.
The associations between preoperative CRP, CYFRA 21-1, and clinicopathologic parameters (N = 130)
| CRP | CYFRA 21-1 | |||||
|---|---|---|---|---|---|---|
| Negative (n (%)) | Positive (n (%)) | P value | Negative (n (%)) | Positive (n (%)) | P value | |
| Pathologic tumor status | ||||||
| Earlya (n = 74) | 64 (86.5) | 10 (13.5) | <0.001 e | 66 (89.2) | 8 (10.8) | 0.308 |
| Advancedb (n = 56) | 29 (51.8) | 27 (48.2) | 46 (82.1) | 10 (17.9) | ||
| Pathologic N stage | ||||||
| N0 (n = 68) | 54 (79.4) | 14 (20.6) | 0.049 | 59 (86.8) | 9 (13.2) | 0.024 |
| N1 (n = 25) | 18 (72.0) | 7 (28.0) | 25 (100.0) | 0 (0.0) | ||
| N2 (n = 37) | 21 (56.8) | 16 (43.2) | 28 (75.7) | 9 (24.3) | ||
| Nodal status | ||||||
| (−) metastasis, (−) ECS (n = 68) | 54 (79.4) | 14 (20.6) | 0.014 | 59 (86.8) | 9 (13.2) | 0.039 |
| (+) metastasis, (−) ECS (n = 23) | 18 (78.3) | 5 (21.7) | 23 (100.0) | 0 (0.0) | ||
| (+) metastasis, (+) ECS (n = 39) | 21 (53.8) | 18 (46.2) | 30 (76.9) | 9 (23.1) | ||
| Differentiation | ||||||
| Well (n = 32) | 21 (65.6) | 11 (34.4) | 0.304 | 29 (90.6) | 3 (9.4) | 0.689 |
| Moderate (n = 80) | 61 (76.2) | 19 (23.8) | 68 (85.0) | 12 (15.0) | ||
| Poor (n = 18) | 11 (61.1) | 7 (38.9) | 15 (83.3) | 3 (16.7) | ||
| Tumor stage | ||||||
| Earlyc (n = 45) | 40 (88.9) | 5 (11.1) | 0.002 e | 38 (84.4) | 7 (15.6) | 0.791e |
| Advancedd (n = 85) | 53 (62.4) | 32 (37.6) | 74 (87.1) | 11 (12.9) | ||
| Skin invasion | ||||||
| No (n = 117) | 88 (75.2) | 29 (24.8) | 0.009 e | 102 (87.2) | 15 (12.8) | 0.389e |
| Yes (n = 13) | 5 (38.5) | 8 (61.5) | 10 (76.9) | 3 (23.1) | ||
| Bone invasion | ||||||
| No (n = 105) | 83 (79.0) | 22 (21.0) | <0.001 e | 91 (86.7) | 14 (13.3) | 0.750e |
| Yes (n = 25) | 10 (40.0) | 15 (60.0) | 21 (84.0) | 4 (16.0) | ||
| Tumor depth ≥10 mm | ||||||
| No (n = 60) | 53 (88.3) | 7 (11.7) | <0.001 e | 54 (90.0) | 6 (10.0) | 0.311e |
| Yes (n = 70) | 40 (57.1) | 30 (42.9) | 58 (82.9) | 12 (17.1) | ||
ECS extracapsular spread
aT1–T2
bT3–T4
cStage I–II
dStage III–IV
eFisher’s exact test